Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin for Disseminated MAC in AIDS (ACTG 157)
NCT00000644Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Nov 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clarithromycin in Mycobacterium avium complex infection (MAC) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Colony-Forming Units of M. avium complex at 12 weeks. Status: completed.
02
Drugs
clarithromycin
03
Conditions
Mycobacterium avium complex infection (MAC)
Beyond the preview
Go deeper on NCT00000644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000644.